SCHEMBL5048672

SCHEMBL5048672

C=CCNC(=O)c1cc(-c2csc(-c3ccc(OC)cc3)n2)n(CC(C)C)c1C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KLKB1 P03952 4/20 0.47
MAPT P10636 7/20 0.46
HPGD P15428 5/20 0.46
SMN1; SMN2 Q16637 5/20 0.46
KDM4E B2RXH2 4/20 0.46
NPC1 O15118 4/20 0.46
RAB9A P51151 4/20 0.46
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
CYP3A4 P08684 2/20 0.45
CYP2C19 P33261 2/20 0.45
POLB P06746 2/20 0.45
LMNA P02545 2/20 0.45
NPSR1 Q6W5P4 1/20 0.45
PPARG P37231 1/20 0.43
NCOA2 Q15596 1/20 0.43
NCOA1 Q15788 1/20 0.43
NCOA3 Q9Y6Q9 1/20 0.43
ALDH1A1 P00352 3/20 0.41
PKM P14618 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5044164 0.91 KLKB1 (0.51) KLKB1MAPTHPGDSMN1; SMN2KDM4E
SCHEMBL5043301 0.90 KLKB1 (0.53) KLKB1MAPTHPGDSMN1; SMN2KDM4E
SCHEMBL5039543 0.88 HPGD (0.52) KLKB1MAPTHPGDSMN1; SMN2KDM4E
SCHEMBL5047799 0.87 HPGD (0.51) KLKB1MAPTHPGDSMN1; SMN2KDM4E
SCHEMBL5044878 0.85 MAPT (0.52) KLKB1MAPTHPGDSMN1; SMN2KDM4E
SCHEMBL5043717 0.85 KDM4E (0.53) KLKB1MAPTHPGDSMN1; SMN2KDM4E
SCHEMBL5039872 0.85 KLKB1 (0.46) KLKB1MAPTHPGDSMN1; SMN2KDM4E
SCHEMBL5046920 0.85 KLKB1 (0.46) KLKB1MAPTHPGDSMN1; SMN2KDM4E
SCHEMBL5046987 0.85 KLKB1 (0.48) KLKB1MAPTHPGDSMN1; SMN2KDM4E
SCHEMBL5043851 0.85 SMN1; SMN2 (0.48) KLKB1MAPTHPGDSMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1583762-B1 PYRROLYL-THIAZOLES AND THEIR USE AS CB 1 RECEPTOR INVERSE AGONISTS HOFFMANN LA ROCHE (CH) 2008-07-09 EP disclosed
US-7135488-B2 Pyrrolyl-thiazole derivatives HOFFMANN-LA ROCHE INC. (US) 2006-11-14 US disclosed
EP-1583762-A1 PYRROLYL-THIAZOLES AND THEIR USE AS CB 1 RECEPTOR INVERSE AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2005-10-12 EP disclosed
US-20040147572-A1 Novel pyrrolyl-thiazole derivatives HOFFMAN-LA ROCHE INC. 2004-07-29 US disclosed
WO-2004060888-A1 NOVEL CB 1 RECEPTOR INVERSE AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2004-07-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040147572-A1 Novel pyrrolyl-thiazole derivatives CNR1, CNR2, NPY1R KLKB1 3949/4885MAPT 3334/4885HPGD 2000/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.